Clinical Trials

237 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

NCT06985147 2026-03-04

A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

60 enrolled

Polycythemia Vera

NCT07232290 2026-03-04

Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

60 enrolled

Polycythemia Vera

NCT05143957 2026-01-16

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

50 enrolled

Polycythemia Vera

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03874858 2026-01-06

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 1 FDA

Eosinophilia, Myeloproliferative Disorders

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

104 enrolled 11 charts

Phase 2 Enrolling by invitation

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

332 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00726232 2025-10-29

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

73 enrolled 25 charts

Myeloproliferative Disorders

NCT05358808 2025-09-30

ACHIEVE

16 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03731260 2025-09-23

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

251 enrolled

Mastocytosis, Systemic

NCT06397313 2025-09-23

POTAMI-61

230 enrolled

Neoplasm Metastasis, Primary Myelofibrosis

NCT05223920 2025-09-22

MK-3543-005

81 enrolled 13 charts

Thrombocythemia, Essential, Primary Myelofibrosis

NCT06514534 2025-09-22

ASC4TARGET

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

29 enrolled 15 charts

Myeloproliferative Disorders, Polycythemia Vera

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

4 enrolled 10 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT05482971 2025-08-13

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

91 enrolled

Myeloproliferative Disorders, Neoplasms, Thrombocythemia, Essential, Thrombocytosis

NCT04057040 2025-08-07

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

70 enrolled

Polycythemia Vera

NCT05485948 2025-08-03

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

49 enrolled

Polycythemia Vera

NCT05558696 2025-07-29

MK-3543-004

20 enrolled

Polycythemia Vera

NCT04996875 2025-05-30

APEX

140 enrolled

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Leukemia, Leukemia, Mast-Cell, Leukemia, Myeloid, Mastocytosis, Myeloproliferative Disorders, Neoplasms, Neoplasms by Site, Neoplasms, Connective Tissue, Skin Diseases, Soft Tissue Neoplasms, Urticaria Pigmentosa, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Mastocytosis, Systemic

NCT06243458 2025-05-22

(MDS)

41 enrolled

Low Risk Myelodysplastic Syndromes

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

90 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

107 enrolled 1 FDA

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

84 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04233346 2025-04-04

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

93 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

33 enrolled 7 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05583552 2025-03-14

IMpress

46 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

144 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01701843 2025-02-24

Cromoglicate in Mastocytosis

7 enrolled

Mastocytosis

NCT06453902 2025-02-21

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

40 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

155 enrolled 24 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04762875 2024-11-06

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

7 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00285259 2024-10-21

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

112 enrolled

Communicable Diseases, Cytomegalovirus Infections, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Viremia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00042003 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

40 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03441113 2024-05-16

Extended Access of Momelotinib in Adults With Myelofibrosis

237 enrolled

Neoplasms, Primary Myelofibrosis

NCT04655118 2024-05-10

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

121 enrolled

Mastocytosis, Systemic, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

74 enrolled 40 charts

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

NCT04767802 2024-03-18

PACIFIC

20 enrolled

Polycythemia Vera

NCT03625388 2023-09-22

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

56 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Classical hematologyMyeloid

95 enrolled 32 charts

Anemia, Primary Myelofibrosis

NCT04631211 2023-05-25

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Classical hematologyMyeloidOther hematologic neoplasm

21 enrolled

Anemia, Aplastic, Myelodysplastic Syndromes, Myeloproliferative Disorders, Thrombocytopenia, Hematologic Neoplasms

NCT02775903 2023-02-28

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

213 enrolled 35 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05612633 2022-11-10

AP-MPN

Phase 2 Withdrawn

Myeloproliferative Disorders

NCT01736683 2022-10-24

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)